Medically, software safety and security issues have become the most crucial topic in the new age of healthcare, when digital health technologies have more and more influence on patient outcomes. As software is used in hospitals, clinics, and by practitioners for treatment decisions and to handle complex workflows, regulations serve as the basis for trust between developers and the medical community. One such standard, ISO 13485, sets the quality management system standard for the medical device industry, including software that is classified as a medical device.
ISO 13485 is an international standard that outlines a quality management system framework for medical devices, designed, developed, and maintained to meet regulatory and customer requirements consistently. The standard also covers medical software that has a diagnostic or therapeutic influence. To obtain this certification, a company must demonstrate compliance with requirements in areas such as documentation, risk management, design validation, supplier control, and post-market surveillance.
For healthcare-related software developers, ISO 13485 provides confidence that products have been developed and maintained under a quality management system that supports patient safety and meets regulatory requirements. Usually, the certification step includes independent audits, internal quality assessments, and checks of error-minimization and traceability procedures throughout a product’s lifecycle.
Altai Oncology, a company that provides health information technology solutions and specializes in hematology and oncology software, is a good example of such a company that works under this strict framework. Its sister company in Turkey is Altay Tıp Sağlık Yazılım AŞ, which is ISO 13485 certified.
Altai Oncology was founded in 2013 in Sheridan, Wyoming, by Ulas Darda Bayraktar, and has been developing digital tools for oncology care. The cancer centers, infusion clinics, and oncology specialists use the platforms for chemotherapy management, protocol reference, and clinical documentation. Altai is working in the U.S. and Turkey, where its research and software development are primarily conducted. They aim to develop digital tools for cancer treatment, such as the Altai Oncology Suite and the Altai Oncology Mobile App.
The ISO 13485 certification of Altai’s Turkish division is a testament to the company’s systematic compliance approach. It is about the company’s ongoing engagement in internal auditing, periodic risk reviews, and the recording of corrective actions to ensure ongoing compliance with the certificate requirements. Altai validates and verifies every product release, aligning with the standard’s emphasis on quality assurance and patient safety.
Keeping certification is like a continuous challenge. It also implies conducting a periodic external audit, underscoring the certification holder’s role as a preserver of the highest standards. For Altai, it means continually enhancing workflows so that task initiation, testing, and implementation comply with the requirements set by international medical device regulators.
The ISO 13485 certification for Altai is directly related to how their software products are developed, maintained, and marketed. One of the company’s main products, the Altai Oncology Suite, is CE-marked as a Class IIb medical device under the European Medical Device Regulations (MDR). This categorization indicates that the software is helpful in the medical decision-making process and supports patient care; therefore, its development needs to undergo strict regulatory control.
By certification standards, what adds up to the oncological suite and the ancillary items, such as the Altai Oncology Mobile App and the Altai Chemo Planner, is the in-depth design controls, documentation review, and quality validations before the final healthcare users receive them. These activities are very helpful in ensuring product reliability and consistency, especially in the functionalities related to chemotherapy dose calculations, order management, and clinical recordkeeping.
In practice, ISO 13485 compliance implies that every element of the software, from data encryption to dose calculation algorithms, must be traceable and tested. Moreover, the standard places particular emphasis on user feedback, which is part of post-market evaluation processes. These give the company a way to monitor the product’s performance in the real world and make changes where necessary.
First of all, for healthcare providers, ISO 13485 certification provides a safety net for the reliability of medical software. Oncology specialists rely on digital systems to manage complex treatment regimens involving cytotoxic drugs, individualized dosing, and strict procedural sequencing. The presence of a certified quality management system is a guarantee that the assets used in those procedures were developed in a controlled, verifiable environment.
Patients can also see the certification as making the systems that support their treatment more reliable. Adherence to internationally accepted safety standards in the software used by the medical profession minimizes the risk of errors in data handling, dose calculation, or protocol selection. This highly structured approach, in the long run, makes the healthcare system, where software is increasingly becoming a critical component of care delivery, sturdier.
The chemotherapeutic capabilities of the Altai Oncology Suite encompass order entry, scheduling, inventory management, and reporting. These characteristics operate under the same quality and compliance framework as required by ISO 13485, thereby ensuring that updates, patches, and new functionalities are development-consistent and under oversight. Hence, the certification serves as both a regulatory safety net and a mechanism for continuous quality assurance.
By holding an ISO 13485 certificate, the company, like Altai Oncology, can stay abreast of the changing international regulatory environment and emerging clinical requirements while enhancing its medical software role. The compliance encourages the company to collaborate with the regulatory authorities, hospitals, and research institutions that favor certified partners in their procurement and integration processes.
Altai’s certification demonstrates that the company meets the requirements for medical safety, quality management, and transparency. It actually goes beyond the requirements and is a system-wide pledge to continue, in due course, with procedures that comply with both patient safety and software reliability demands.
Altai is projected to continue improving processes through frequent audits, user feedback assessments, and risk management evaluations. The influence of ISO 13485 certification over a long period extends beyond the quality of products and to the healthcare providers’ confidence, who are reliant on digital systems for the delivery of oncology care. In a world where technology and medicine eventually become one, following global standards remains the basis of trust; thus, innovation moves at the same pace as accountability.
